Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
2024 · Blood Cancer Journal · 32 citations
https://doi.org/10.1038/s41408-024-01043-5
C
Carlyn Tan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
252
Papers
3.2K
Citations
26
h-index
42
i10-index
Carlyn Tan is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & CAR-T cell therapy research & Protein Degradation and Inhibitors. The author has an h-index of 26, co-authored 215 publications.
ORCID: 0000-0001-7922-2594Papers by this author
worksPrognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
2024 · Blood Cancer Journal · 26 citations
https://doi.org/10.1038/s41408-024-01048-0
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
2025 · Blood Cancer Journal · 26 citations
https://doi.org/10.1038/s41408-025-01259-z
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
2023 · Blood Cancer Journal · 18 citations
https://doi.org/10.1038/s41408-023-00882-y
A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
2025 · Cancer Discovery · 5 citations
https://doi.org/10.1158/2159-8290.cd-25-1101
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience
2025 · Blood Neoplasia · 3 citations
https://doi.org/10.1016/j.bneo.2025.100103
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat